An international study led by researchers from the Sant Pau Research Institute (IR Sant Pau) shows that advanced use of ...

A novel blood and cerebrospinal fluid (CSF) measure showed promise as a biomarker for Parkinsonian disorders. CSF levels of DOPA decarboxylase (DDC) -- an enzyme that converts levodopa into dopamine - ...

Attention has turned to progressive supranuclear palsy, a rare neurodegenerative disorder. Here's what it is and why it's often mistaken for Parkinson’s disease.

University of Florida researchers have led a multicenter study demonstrating that Automated Imaging Differentiation for ...

Atypical parkinsonism, or the so-called Parkinson-plus syndromes, does not respond to dopaminergic or other therapies that are used for Parkinson's disease. The 2 most common of these conditions are ...

Hearing impairment is a common nonmotor manifestation of Parkinson disease, often involving high-frequency hearing loss.

With several fluid biomarkers for Alzheimer’s in hand, the search is on for counterparts in Parkinson’s disease and dementia with Lewy bodies (DLB). Four new papers introduce two candidates: DOPA ...

Parkinson's disease affects millions of people around the world. There are actually 10 million people on a worldwide scale that have the neurodegenerative disorder, according to the Parkinson's ...